Business
Half Yearly Report
Half Yearly Report.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n RNS Number : 1779H Sareum Holdings PLC 16 February 2010 \n\n\n\n\n\n\n\n\n 16 February 2010\n\n\n\n\n \nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\n \nHALF YEARLY RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2009\n \nSareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce its half-yearly results for the six month period ended 31 December 2009.\n \nFinancial highlights \n· Cash at bank at period end was £740,000 (2008: £531,000)\n· Loss on ordinary activities (after taxation) of £296,000 (2008: £848,000)\n· Placing of £815,000 (gross) in the period to advance cancer drug pipeline\n \nOperational highlights\n· Research programmes making good progress\n· Progress in Chk1 cancer programme presented at NCRI cancer conference\n· Company showcase presentation at BIO-Europe, Europe's largest biotechnology partnering event\n \nPost period end highlights\n· Progress in Chk1 cancer programme published in peer-reviewed scientific journal\n \nDr Tim Mitchell, CEO of Sareum Holdings plc, said: \"We have been actively progressing and marketing our cancer research programmes and the recent fundraisings provide us with sufficient cash for the foreseeable future.\"\n \n\n\n\n\nSareum Holdings plc\n\n\n\n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\n\n\n\n\n\n\n\n\nMerchant John East Securities Limited\n\n\n\n\n\n\n\nSimon Clements/Bidhi Bhoma\n\n\n020 7628 2200\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP\n\n\n\n\n\n\n\nClaire Noyce/Stephen Austin\n\n\n020 7947 4350\n\n\n\n\n \n \n\n\nHalf-yearly results for the six months ended 31 December 2009\n \nChairman's Statement\nSareum continues to progress its in-house cancer drug pipeline, whilst managing the research spend such that we can drive the most promising lines of development to build the asset value of our programmes.\nSareum's most advanced in-house programme is carried out in conjunction with one of the world's leading cancer research organisations, The Institute of Cancer Research and Cancer Research Technologi...